KRTL Holding Group Inc. (OTC: KRTL) is growing its presence in South America, focusing on Bolivia’s potential in biopharmaceutical innovation. KRTL’s subsidiaries, KRTL Biotech Inc. and KRTL International Corp., have established a joint venture with Centro de Investigaciones Químicas – CIQ S.R.L., a Bolivian research institution led by Dr. Marcelo Bascope.
The joint venture includes a 19.98% stake in 3,451.5 acres of land in the Amazon region, acquired through negotiations with the Bolivian government. This partnership aims to improve sustainable API extraction, conduct advanced research and enhance manufacturing capabilities.
KRTL Biotech plans to introduce CIQ’s products to the U.S. market, ensuring compliance with FDA registration requirements and international regulations for a smoother market entry. This collaboration aims to improve market accessibility for CIQ’s natural-based innovations.
CIQ specializes in extracting high-value botanical ingredients from Bolivia’s ecosystems. Bascope stated, “This joint venture expands CIQ’s potential far beyond Bolivia, allowing us to introduce our botanical extracts and APIs to new markets while advancing scientific research through KRTL Biotech’s regulatory expertise.”
The venture will support the development of three facilities in Quillacollo, Santa Cruz and Cochabamba. KRTL International will manage infrastructure development, including carbon credit initiatives, while KRTL Biotech will focus on regulatory compliance.
Additionally, the partnership will provide access to CIQ’s library of exotic molecules, which will undergo FDA review for potential applications in pain management and dermatology. With partnerships at over 40 international universities, CIQ aims to further research in molecular biology and sustainable chemistry.
Lakewood-based KRTL Holding’s expansion into Bolivia reflects a strategic approach for economic and environmental sustainability. Cesar Herrera, CEO, stated, “KRTL continues to expand strategically, forming key international collaborations to strengthen market access, supply chain control, operational capabilities and enhancing our partnerships, which combined with our FDA registrations, gives us the ability to sell pharmaceutical products from Bolivia in the US.”
This move signals a shift in KRTL Biotech’s strategy toward sustainable pharmaceutical production, leveraging Bolivia’s biodiversity and investment in research.
